Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Update

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 500,700 shares, a growth of 161.3% from the January 31st total of 191,600 shares. Approximately 6.4% of the shares of the company are sold short. Based on an average daily volume of 3,200,000 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of Cumberland Pharmaceuticals

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Two Sigma Investments LP boosted its position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,649 shares of the specialty pharmaceutical company’s stock after purchasing an additional 18,271 shares during the quarter. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Stock Down 2.2 %

NASDAQ:CPIX opened at $4.86 on Friday. Cumberland Pharmaceuticals has a twelve month low of $1.04 and a twelve month high of $7.19. The company has a market cap of $68.24 million, a price-to-earnings ratio of -6.31 and a beta of 0.12. The stock has a fifty day simple moving average of $3.39 and a 200-day simple moving average of $2.07. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals in a research note on Friday, February 14th. They issued a “hold” rating on the stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.